Advertisement
News
Advertisement

Bionovo to Present Tissue Selective Estrogen Receptor Modulators for Obesity at the 22nd Annual Meeting of the North American Menopause Society

Tue, 09/20/2011 - 5:34am
Bio-Medicine.Org

EMERYVILLE, Calif., Sept. 20, 2011 /PRNewswire/ -- Bionovo, Inc. (NASDAQ: BNVI), a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced that Dr. Mary Tagliaferri, President and Chief Medical Officer of Bionovo, will present the results of a study on the effects of two botanically-derived, tissue selective estrogen receptor modulators for the treatment of obesity at the 22nd Annual Meeting of the North American Menopause Society (NAMS) in Washington DC on Friday, September 23, 2011.

On average, women transitioning through menopause experience a 10-15 pound weight gain with a redistribution of fat to the abdomen. Menopausal changes of body weight and increased central distribution of body fat have been identified as independent predictors of cardiovascular disease and type 2 diabetes. Dr. Tagliaferri will present studies that identify a new class of botanically-derived, tissue selective estrogen receptor modulators in adipose tissue which cause weight loss in mice without the unwanted proliferative effects in breast and uterine tissue that are associated with cancer.

In this study, ovariectomized female mice, mimicking menopause, were placed on a high fat diet for one month prior to initiation of treatment. While the untreated mice continued to gain weight, the mice administered with estrogens or the botanically-derived tissue selective estrogen receptor modulators lost weight. While estrogens had positive effects on the body fat mass, they significantly increased the size of the mammary gland and uterus. In contrast, the botanically-derived tissue selective estrogen receptor modulators did not adversely affect either the breast or uterine tissue. These findings suggest that the development of botanically-derived, tissue selective estrogen receptor modulators result in safer altern

'/>"/>

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading